Insider Transactions in Q3 2025 at Johnson & Johnson (JNJ)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 04
2025
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
SELL
Open market or private sale
|
Direct |
56,471
-24.08%
|
$9,995,367
$177.81 P/Share
|
|
Sep 04
2025
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
BUY
Exercise of conversion of derivative security
|
Direct |
56,471
+19.41%
|
$5,703,571
$101.87 P/Share
|
|
Aug 29
2025
|
Elizabeth Forminard Executive VP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
9,570
-42.68%
|
$1,693,890
$177.2 P/Share
|
|
Aug 29
2025
|
Elizabeth Forminard Executive VP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
11,521
+33.94%
|
$1,324,915
$115.67 P/Share
|
|
Aug 22
2025
|
Joaquin Duato CEO and Chairman of the Board |
SELL
Open market or private sale
|
Direct |
125,824
-31.32%
|
$22,522,496
$179.21 P/Share
|
|
Aug 22
2025
|
Joaquin Duato CEO and Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
125,824
+23.85%
|
$12,708,224
$101.87 P/Share
|
|
Aug 15
2025
|
Joseph J Wolk Exec VP, CFO |
SELL
Open market or private sale
|
Direct |
16,820
-54.58%
|
$2,960,320
$176.91 P/Share
|
|
Aug 15
2025
|
Joseph J Wolk Exec VP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,820
+35.31%
|
$1,698,820
$101.87 P/Share
|
|
Jul 17
2025
|
John C Reed EVP, Innovative Medicine, R&D |
SELL
Open market or private sale
|
Direct |
19,137
-64.23%
|
$3,119,331
$163.55 P/Share
|